Global Transdermal Patches Market Outlook to 2030

Global Transdermal Patches Market Overview

Global Transdermal Patches Market was valued at USD 6 billion in 2023, driven by advancements in medical diagnostics and increasing incidences of bloodstream infections. Enhanced diagnostic accuracy and faster results have led to higher adoption rates in both developed and developing regions.

Key players in the global transdermal patches market include Novartis AG, Mylan N.V., Teva Pharmaceutical Industries Ltd., Hisamitsu Pharmaceutical Co., Inc., and Glaxo Smith Kline plc. These companies are leaders due to their extensive product portfolios, significant investments in R&D, and strong global distribution networks.

In 2023, Hisamitsu Pharmaceutical Co., Inc. proudly announced that its flagship product Salonpas has been recognized as the world's No. 1 OTC topical analgesic patch brand for the seventh consecutive year since 2016. This achievement is based on comprehensive global market research conducted by Euromonitor International.

The transdermal patches market is dominated by cities in North America and Europe, particularly New York, San Francisco, and Berlin. New York and San Francisco are home to leading biotech and pharmaceutical companies that drive innovation in transdermal technologies. Berlin, with its robust healthcare infrastructure and strong presence of R&D centers, plays a crucial role in the European market.

Global Transdermal Patches Market Segmentation

The Global Transdermal Patches Market can be segmented based on several factors:

By Product Type: Global Transdermal Patches Market is segmented by product type into pain relief patches, hormone patches, nicotine patches, and others. In 2023, pain relief patches held a dominant market share, driven by the increasing incidence of chronic pain conditions such as arthritis and neuropathy. The convenience of pain management through transdermal patches, coupled with the growing preference for non-opioid treatments, has solidified their position in the market.

By Application: The transdermal patches market is also segmented by application into cardiovascular diseases, central nervous system disorders, hormone replacement therapy, and smoking cessation. In 2023, the segment for central nervous system (CNS) disorders dominated the market. This dominance is primarily due to the increasing prevalence of diseases such as Parkinsons and Alzheimers, which require consistent medication that transdermal patches provide effectively.

By Region: Global Transdermal Patches Market is segmented by region into North America, Europe, Asia-Pacific, Latin America, Middle East & Africa regions. In 2023, North America region is dominating this segment. North America, particularly the United States, has one of the most advanced healthcare infrastructures in the world. This includes a high number of hospitals, diagnostic laboratories, and research institutions equipped with state-of-the-art technology and facilities.

Global Transdermal Patches Market Competitive Landscape

Company

Establishment Year

Headquarters

Novartis AG

1996

Basel, Switzerland

Mylan N.V.

1961

Canonsburg, Pennsylvania

Teva Pharmaceutical

1901

Tel Aviv, Israel

Hisamitsu Pharmaceutical

1847

Tosu, Japan

Glaxo Smith Kline plc

2000

Brentford, United Kingdom

Novartis & Corium Agreement: In 2023, Novartis completed its transformation into a pure-play innovative medicines business.The company now has a clear focus on four core therapeutic areas: Cardiovascular, renal and metabolic, Immunology, Neuroscience, and Oncology.
.

Johnson & Johnson: In 2024, Johnson & Johnson has received expanded approval for CARVYKTI (ciltacabtagene autoleucel), a therapy for multiple myeloma. This approval follows the successful Phase 3 CARTITUDE-4 study, which demonstrated a significant reduction in disease progression or death compared to traditional therapies

Global Transdermal Patches Industry Analysis

Growth Drivers:

Increasing Prevalence of Chronic Diseases: The World Health Organization (WHO) has reported that approximately 1.28 billion adults aged 30 to 79 years worldwide are affected by hypertension. Nitroglycerin patches are used to relax blood vessels and lower the frequency of angina in patients with heart disease.

Aging Population and Geriatric Care: According to UNFPA, the global share of people aged 65 and over has nearly doubled from 5.5% in 1974 to 10.3% in 2024. The elderly are more susceptible to chronic conditions that require long-term medication, making them prime candidates for transdermal drug delivery systems.

Technological Advancements in Drug Delivery Systems: Design of a microneedle patch that can painlessly deliver immune-regulating molecules to the scalp, helping reverse hair loss caused by alopecia areata. These advancements are expected to expand the range of conditions treatable by transdermal patches, thus opening new market segments and enhancing the overall market potential.

Challenges
:

Regulatory Hurdles and Approval Delays: In 2023, the U.S. FDA delayed the approval of a new transdermal patch for Parkinsons disease by 18 months due to concerns over its adhesive properties and skin irritation potential. These regulatory challenges often lead to increased development costs and extended time-to-market, which can negatively impact the financial viability of new products and slow down innovation in the market.

Skin Reactions and Side Effects: Another challenge for the transdermal patches market is the incidence of skin reactions and other side effects like allergies & skin irritation. These adverse effects can lead to discontinuation of treatment and a preference for alternative drug delivery methods, thereby limiting the growth of the market.

Government Initiatives:

U.S. FDAs Drug Competition Action Plan: The U.S. FDA's Drug Competition Action Plan (DCAP) was launched in 2017. Subsequently, the FDA published updated list of off-patent, off-exclusivity drugs without approved generics (OPOE list) in June 2024. The FDAs streamlined approval process for generics, including transdermal patches, has resulted in a faster time-to-market for these product.

European Medicines Agency (EMA) Guidelines for Transdermal Drug Delivery Systems: The European Medicines Agency (EMA) has established guidelines for Transdermal Drug Delivery Systems (TDDS) to ensure the efficacy, safety, and quality of these formulations. Specific requirements for bioequivalence studies for generic TDDS are detailed, focusing on factors such as skin adhesion, delivery rate, and pharmacokinetic parameters relevant to absorption.

Global Transdermal Patches Future Market Outlook

The Global Transdermal Patches Market is projected to reach USD 11.7 billion by 2030, driven by the increasing demand for non-invasive drug delivery systems and the growing prevalence of chronic diseases.

Future Market Trends

Expansion of Indications for Transdermal Patches: In the coming years, the range of medical conditions treated with transdermal patches is expected to expand significantly. Researchers are exploring the use of patches for delivering vaccines, insulin, and even chemotherapy drugs, which could revolutionize treatment protocols for a variety of diseases.

Integration of Smart Technologies: The future of transdermal patches will likely include the integration of smart technologies, such as sensors that monitor drug delivery and patient adherence. These advanced patches will be able to provide real-time data to healthcare providers, enabling more personalized and effective treatment plans.
Please Note: It will take 5-7 business days to complete the report upon order confirmation